Information  X 
Enter a valid email address

IXICO plc (IXI)

  Print   

Thursday 21 January, 2021

IXICO plc

Result of AGM

RNS Number : 4748M
IXICO plc
21 January 2021
 

 

 

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

 

Resolution

Description

Total Votes For

% Votes

Total Votes Against

Withheld

1

Reports and Accounts

 

30,185,052

99.95%

 

15,600

400

2

Re-election of Directors

 

 

 

 

Re-election of Mark Warne

 

30,185,152

 

99.95%

15,900

 

0

 

Re-election of John Bradshaw

30,185,452

99.95%

15,600

0

3

Re-appointment of Auditors

 

30,065,960

99.57%

128,100

6,992

4

Allotment of Securities

 

30,180,960

99.94%

17,100

2,992

5

Disapply Pre-Emption Provisions

 

30,180,010

99.94%

18,050

2,992

6

Amendment of rule 3.6.1 of the Company's 2014 EMI Share Option Plan

 

30,165,610

99.89%

33,350

1,992

 

For further information please contact:

 

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

 

Michael F Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

+44 (0)20 7933 8780  

Paul McManus /  Lianne Cawthorne /

[email protected]

Alice Woodings

 

 

 

 

 

 

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

 

More information is available on   www.IXICO.com   and follow us on Twitter @IxicOplc  

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGDKDBPKBKDFDB

a d v e r t i s e m e n t